Topics

Clinical Challenges: Immunotherapy and Chemo in NSCLC

10:00 EST 8 Nov 2019 | MedPageToday

(MedPage Today) -- Several studies have shown that adding immune checkpoint inhibitors to chemotherapy is a superior approach to chemotherapy alone for treating patients with advanced or metastatic non-small cell lung cancer (NSCLC). Does that...

Original Article: Clinical Challenges: Immunotherapy and Chemo in NSCLC

NEXT ARTICLE

More From BioPortfolio on "Clinical Challenges: Immunotherapy and Chemo in NSCLC"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...